AmoyDx
The NGS solution for clinical oncology
AmoyDX delivers innovative Next-Generation Sequencing-based solutions to aid in the diagnosis and treatment of tumors and cancers.
Amoy Diagnostics Co., Ltd. (AmoyDx) is an R&D based diagnostic company, focusing on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS®, Super-ARMS®, ddCapture® and ADx-HANDLE® technologies. In the past years, more than 20 diagnostic kits have been approved by the Chinese authorities, the NMPA and in Europe (CE mark). In several External Quality Assessment (EQA) programs, including EMQN and PQCC, AmoyDx is the NO. 1 testing kit supplier for years and always achieves the highest accuracy rates.
Nowadays, AmoyDx serves an extensive domestic and international oncology network, reaching over 500 top hospitals in China and over 50 countries worldwide. Every year hundreds of thousands of cancer patients benefit from AmoyDx products and services. As diagnostic partner with AstraZeneca, Johnson & Johnson, Amgen, Eli Lilly, Merck, Eisai, Hengrui and BeiGene, AmoyDx provides diagnostic products and services for trials of drugs in clinical development and for clinical practice. AmoyDx® ROS1 kit was the first approved companion diagnostic kit for Pfizer's crizotinib by Japanese and South Korean authorities.
Classic NGS Panel
AmoyDx® HANDLE Classic NGS Panel was developed with HANDLE technology and targeting 32 cancers driver genes and novel biomarkers (such as the NTRK1-3 gene, FGFR1-3). This test kit allows you to detect SNVs, InDels, Fusions, and CNVs from FFPE tissue samples with a sensitivity as high as 98%.
HRD Focus Panel
AmoyDx® HRD Focus Panel is a kit that developed to know the status of the deficiency the homologous recombination (HRD) of the patient. This kit detects the entire CDS and splicing region of the BRCA1/2 gene. The advantage of this kit is that it's able to determine the status of the genomic scar score (GSS) of the patient using a validated probe.
